Walters R S, Theriault R L, Holmes F A, Hortobagyi G N, Esparza L
University of Texas M.D. Anderson Cancer Center, Department of Medical Oncology, Houston 77030.
Invest New Drugs. 1992 Apr;10(1):43-4. doi: 10.1007/BF01275480.
Fourteen consecutive female patients with metastatic breast cancer received a total of 31 courses of fazarabine at a dose of 2 mg/m2/hour x 72 hours (48 mg/m2/day x 3) as a continuous infusion. There were no responses seen, although one patient achieved stability of her disease for five courses. Because of encouraging in vitro results and the primarily hematologic dose-limiting toxicity, further study in combination with colony stimulating growth factors might be of interest.
